DuPont de Nemours Inc operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares DuPont de Nemours Inc with three other
pharmaceutical manufacturers in North America:
Gilead Sciences, Inc.
sales of $24.69 billion
of which 100%
was discovery, development and commercializa),
of which 26%
was Other products), and
Eli Lilly and Company
of which 29%
was Oncology-Verzenio & Other).
During the year ended December of 2020, sales at
DuPont de Nemours Inc were $20.40 billion.
decrease of 5.2%
versus 2019, when the company's sales were $21.51 billion.
Contributing to the drop in overall sales was the 22.5% decline
in Non-Core, from $1.73 billion to $1.34 billion.
There were also decreases in sales in
Nutrition and Biosciences (down 0.3% to $6.06 billion)
Safety and Construction (down 4.0% to $4.99 billion)
Transportation and Industrial (down 15.4% to $4.19 billion)
However, these declines were partially offset by the increase in sales of
Electronic and Imaging (up 7.3% to $3.81 billion)